Table 1: Baseline features of all patients evaluated at baseline (mean ± standard deviation).

Group
Placebo (n = 23) Creatine (n = 25)
Clinical and anthropometric variables
Age (years) 68.1 ± 4.9 67.5 ± 4.5 NS
Systolic blood pressure (mmHg) 131.0 ± 15.8 128.7 ± 15.4 NS
Diastolic blood pressure (mmHg) 74.1 ± 6.5 74.2 ± 8.1 NS
Usual physical activity (MET-min/week)§ 1,170.5 ± 1,113.2 1,233.4 ± 1,075.0 NS
Mini nutritional assessment 26.2 ± 2.6 26.3 ± 2.6 NS
Body mass index (kg(m2) 29.5 ± 3.9 29.2 ± 4.2 NS
Waist circumference (cm) 96.3 ± 8.7 97.4 ± 10.7 NS
Hip circumference (cm) 104.6 ± 7.9 104.6 ± 8.7 NS
Muscle strength and functional variables
Right hand grip strength (kg) 22.8 ± 4.2 22.1 ± 4.3 NS
Left hand grip strength (kg) 22.2 ± 3.7 20.2 ± 3.4 NS
Right quadriceps torque (N) 233.6 ± 46.2 252.5 ± 63.4 NS
Left quadriceps torque (N) 245.7 ± 70.3 262.6 ± 69.4 NS
Timed up and go (sec) 7.1 ± 0.8 7.2 ± 0.9 NS
12 minutes' walk (m) 944.4 ± 128.4 1,009.8 ± 95.0 NS
Body composition
Total fat free mass (kg) 35.4 ± 4.5 36.0 ± 4.2 NS
Total fat mass (kg) 31.6 ± 7.3 31.0 ± 7.6 NS
Appendicular fat free mass (kg) 14.3 ± 2.3 14.3 ± 2.3 NS
Appendicular fat mass (kg) 12.6 ± 3.2 12.4 ± 2.8 NS
Rectus femoris ultrasound
Right rectus femoris thickness (cm) 17.1 ± 2.8 17.3 ± 2.1 NS
Left rectus femoris thickness (cm) 16.0 ± 3.0 16.2 ± 2.2 NS

= Significance of difference between group placebo and creatine. NS means non-significant
§ = Calculated using the international physical activity questionnaire (IPAQ).